China Targets 25% Share of Global First-in-Class Drugs Market by 2030

China has set its sights on capturing at least a quarter of the world’s first-in-class drugs market by 2030 under a new five-year plan to become a global biomedicine powerhouse.

The plan requires large pharmaceutical enterprises to generate a combined revenue of no less than 3.5 trillion yuan (US$522 billion) driven by technological breakthroughs across critical fields.

As authorities seek to build scale beyond market leaders like Sinopharm, which generated 575 billion yuan last year, the policy outlines 10 measurable targets, including producing at least 50 drugmakers with annual revenue exceeding 10 billion yuan each.

Revenue Targets for Top Drugmakers

Meeting the top-line target requires faster consolidation across state-backed and private drugmakers. Sinopharm, the country’s largest pharmaceutical distributor, generated 575 billion yuan in revenue last year. State planners want to replicate that scale across the manufacturing base.

Reaching 3.5 trillion yuan across leading firms means turning mid-tier developers into commercial powerhouses. These firms must fund long clinical trials. Capital must also shift away from low-margin generics into novel compounds.

Building Scale Across the Supply Chain

Healthcare operators, hospital networks and procurement platforms will see supplier negotiations change. State purchasing programs have spent years cutting generic drug prices. That compressed distribution margins while freeing hospital budgets for innovative therapies.

Institutional investors face a different risk profile across the sector. Backing early-stage discovery brings higher clinical failure rates than reformulating existing drugs. Capital will concentrate around the 50 major players capable of clearing the 10 billion yuan threshold.

Shifting from Generics to Innovation

Commercial drug distribution historically relied on large volumes of off-patent medications to support national healthcare coverage. Domestic intellectual property stayed tied to fast-follower treatments rather than novel biologics.

Recent regulatory reforms sped up drug approvals and aligned domestic clinical trial standards with international norms. The new five-year plan builds directly on that operational base.

The 2030 Benchmarks

Execution hinges on domestic developers clearing late-stage international trials and licensing compounds overseas. Dealmakers are tracking the pace of mergers and pipeline acquisitions needed to build 50 ten-billion-yuan producers before 2030.